About royalty pharma plc - RPRX
Royalty Pharma Plc engages in the provision of drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.
RPRX At a Glance
Royalty Pharma Plc
110 East 59th Street
New York, New York 10022
| Phone | 1-212-883-0200 | Revenue | 2.26B | |
| Industry | Pharmaceuticals: Major | Net Income | 858.98M | |
| Sector | Health Technology | Employees | 99 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
RPRX Valuation
| P/E Current | 25.217 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 13.343 |
| Price to Sales Ratio | 6.695 |
| Price to Book Ratio | 1.638 |
| Price to Cash Flow Ratio | 5.43 |
| Enterprise Value to EBITDA | 19.48 |
| Enterprise Value to Sales | 11.123 |
| Total Debt to Enterprise Value | 0.302 |
RPRX Efficiency
| Revenue/Employee | 22,864,404.04 |
| Income Per Employee | 8,676,595.96 |
| Receivables Turnover | 2.792 |
| Total Asset Turnover | 0.131 |
RPRX Liquidity
| Current Ratio | 1.438 |
| Quick Ratio | 1.438 |
| Cash Ratio | 0.788 |
RPRX Profitability
| Gross Margin | N/A |
| Operating Margin | 57.097 |
| Pretax Margin | 58.793 |
| Net Margin | 37.948 |
| Return on Assets | 4.965 |
| Return on Equity | 12.751 |
| Return on Total Capital | 5.90 |
| Return on Invested Capital | 6.551 |
RPRX Capital Structure
| Total Debt to Total Equity | 109.585 |
| Total Debt to Total Capital | 52.287 |
| Total Debt to Total Assets | 41.774 |
| Long-Term Debt to Equity | 95.222 |
| Long-Term Debt to Total Capital | 45.433 |